Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
16 May 2024
|
|
07:07 | User:AED 4 changes history +102 [Alara E. Dagsali (4×)] | |||
|
|
07:07 (cur | prev) +21 Alara E. Dagsali talk contribs | ||||
|
|
06:42 (cur | prev) +24 Alara E. Dagsali talk contribs | ||||
|
|
06:33 (cur | prev) +27 Alara E. Dagsali talk contribs | ||||
|
|
06:22 (cur | prev) +30 Alara E. Dagsali talk contribs | ||||
|
|
N 07:06 | Diclofenac Patch 2 changes history +48,613 [Alara E. Dagsali (2×)] | |||
|
|
07:06 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
07:06 (cur | prev) +48,610 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=DICLOVIX |indicationType=treatment |indication=Diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). |hasBlackBoxWarning=Yes |adverseReactions=Dry Skin (Application Site) Contact Dermatitis (Application Site) Dyspepsia Abdominal Pain Flatulence Pruritus (Application Site) Diarr...") | |||
|
|
N 06:42 | Cortisone Acetate 2 changes history +14,098 [Alara E. Dagsali (2×)] | |||
|
|
06:42 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
06:42 (cur | prev) +14,095 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Cortisone Acetate |aOrAn=a |indicationType=treatment |indication=When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congen...") | |||
|
|
N 06:33 | Clocortolone Pivalate 2 changes history +4,446 [Alara E. Dagsali (2×)] | |||
|
|
06:33 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
06:32 (cur | prev) +4,443 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Clocortolone Pivalate |indicationType=treatment |indication=Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. |adverseReactions=The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed...") | |||
|
|
N 06:21 | Scorpion 2 changes history +12,448 [Alara E. Dagsali (2×)] | |||
|
|
06:21 (cur | prev) +30 Alara E. Dagsali talk contribs | ||||
| N |
|
06:20 (cur | prev) +12,418 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |genericName=Anascorp |indicationType=treatment |indication=ANASCORP® [centruroides (scorpion) immune F(ab')2 (equine) injection] is an equine-derived antivenom indicated for treatment of patients with clinical signs of scorpion envenomation. |adverseReactions=The most common adverse reactions observed in ≥ 2% of patients in the clinical studies for ANASCORP were: vomiting, pyrexia, rash, nausea and pruritus. |fdaLIADAdult=For Intravenous u...") | |||
|
|
03:47 | Trofinetide 4 changes history +4,143 [Alen Antony (4×)] | |||
|
|
03:47 (cur | prev) +1 Alen Antony talk contribs | ||||
|
|
03:46 (cur | prev) +2,158 Alen Antony talk contribs | ||||
|
|
03:29 (cur | prev) +912 Alen Antony talk contribs | ||||
|
|
03:09 (cur | prev) +1,072 Alen Antony talk contribs | ||||
15 May 2024
|
|
20:44 | Medication reconciliation 2 changes history +536 [Badgettrg (2×)] | |||
|
|
20:44 (cur | prev) +1 Badgettrg talk contribs (→Frequency of reconciliation errors) | ||||
|
|
20:43 (cur | prev) +535 Badgettrg talk contribs | ||||
| 14:58 | Vamorolone diffhist +11,928 Rafael Garcia talk contribs | ||||
|
|
14:21 | User:Archana.vajjala 2 changes history −24 [Archana.vajjala (2×)] | |||
|
|
14:21 (cur | prev) −22 Archana.vajjala talk contribs Tag: Visual edit | ||||
|
|
12:16 (cur | prev) −2 Archana.vajjala talk contribs Tag: Visual edit | ||||
|
|
N 10:59 | Lodoxamide 2 changes history +6,537 [Alara E. Dagsali (2×)] | |||
|
|
10:59 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
10:58 (cur | prev) +6,534 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Alomide |indicationType=treatment |indication=ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% is indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. |adverseReactions=During clinical studies of ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1%, the most frequently reported ocular adve...") | |||
|
|
04:40 | Trofinetide 2 changes history +176 [Alen Antony (2×)] | |||
|
|
04:40 (cur | prev) +41 Alen Antony talk contribs | ||||
|
|
04:40 (cur | prev) +135 Alen Antony talk contribs | ||||
|
|
04:28 | Fezolinetant 8 changes history +4,781 [Alen Antony (8×)] | |||
|
|
04:28 (cur | prev) +1,695 Alen Antony talk contribs | ||||
|
|
04:21 (cur | prev) +1,499 Alen Antony talk contribs | ||||
|
|
03:44 (cur | prev) +174 Alen Antony talk contribs | ||||
|
|
03:37 (cur | prev) +19 Alen Antony talk contribs | ||||
|
|
02:46 (cur | prev) +589 Alen Antony talk contribs | ||||
|
|
02:24 (cur | prev) +234 Alen Antony talk contribs | ||||
|
|
01:32 (cur | prev) +512 Alen Antony talk contribs | ||||
|
|
01:09 (cur | prev) +59 Alen Antony talk contribs | ||||
14 May 2024
|
|
21:44 | Fezolinetant 2 changes history +817 [Alen Antony (2×)] | |||
|
|
21:44 (cur | prev) +723 Alen Antony talk contribs | ||||
|
|
21:34 (cur | prev) +94 Alen Antony talk contribs | ||||
| 04:55 | Somatrogon-ghla diffhist +52 Kosar Doraghi talk contribs | ||||
13 May 2024
| N 23:48 | Fezolinetant diffhist +84 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=fezolinetant }}") | ||||
| 23:46 | Nirsevimab-alip diffhist +3,844 Alen Antony talk contribs | ||||